ARGX Argenx: רווח למניה בשנים עשר החודשים האחרונים

The growth of the Vyvgart patient base and the expansion of indications drive the price action for argenx SE (ARGX), despite pricing pressure from regulators. Revenues are based on the sale of unique antibodies for neurology, while competent management has ensured trial transparency and the successful launch of blockbusters. The rolling net income per share smooths out market noise, while 26.06 reflects the latest value of the metric.

Investors utilize this criterion to assess the real yield of each share, excluding the impact of issuances or share buybacks on the final financial result. The rolling year net income per share reflects the efficiency of argenx SE's transformation from a startup into a commercial leader, confirming management's financial discipline through the growth trend of actual earnings per share.